PCI Biotech Holding ASA
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company's technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vecto… Read more
PCI Biotech Holding ASA (PCIB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.501x
Based on the latest financial reports, PCI Biotech Holding ASA (PCIB) has a cash flow conversion efficiency ratio of -0.501x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-6.26 Million) by net assets (Nkr12.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PCI Biotech Holding ASA - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how PCI Biotech Holding ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
PCI Biotech Holding ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PCI Biotech Holding ASA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Canadian Spirit Resources Inc
PINK:CSPUF
|
0.030x |
|
Sentient Brands Holdings Inc
NASDAQ:SNBHD
|
0.019x |
|
DigiMax Global Inc
PINK:DBKSF
|
-0.088x |
|
US BANCORP (UB5.SG)
STU:UB5
|
0.016x |
|
ELISA - Dusseldorf Stock Exchang
DU:EIA
|
0.156x |
|
SUN HYDRAULICS
BE:SH7
|
0.039x |
|
SeAH Besteel Corp.
KQ:001430
|
N/A |
|
Atlantska Plovidba d.d.
ZSE:ATPL
|
N/A |
Annual Cash Flow Conversion Efficiency for PCI Biotech Holding ASA (2008–2024)
The table below shows the annual cash flow conversion efficiency of PCI Biotech Holding ASA from 2008 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Nkr23.45 Million | Nkr-13.76 Million | -0.587x | -53.00% |
| 2023-12-31 | Nkr39.04 Million | Nkr-14.97 Million | -0.383x | +62.72% |
| 2022-12-31 | Nkr57.40 Million | Nkr-59.04 Million | -1.029x | -71.35% |
| 2021-12-31 | Nkr113.79 Million | Nkr-68.31 Million | -0.600x | -46.79% |
| 2020-12-31 | Nkr189.24 Million | Nkr-77.39 Million | -0.409x | -24.85% |
| 2019-12-31 | Nkr254.83 Million | Nkr-83.47 Million | -0.328x | -258.30% |
| 2018-12-31 | Nkr339.95 Million | Nkr-31.08 Million | -0.091x | +87.51% |
| 2017-12-31 | Nkr41.84 Million | Nkr-30.62 Million | -0.732x | +73.17% |
| 2016-12-31 | Nkr13.09 Million | Nkr-35.69 Million | -2.728x | -267.80% |
| 2015-12-31 | Nkr44.28 Million | Nkr-32.84 Million | -0.742x | +78.66% |
| 2014-12-31 | Nkr9.11 Million | Nkr-31.67 Million | -3.475x | -427.45% |
| 2013-12-31 | Nkr43.40 Million | Nkr-28.59 Million | -0.659x | -88.59% |
| 2012-12-31 | Nkr69.71 Million | Nkr-24.35 Million | -0.349x | -69.72% |
| 2011-12-31 | Nkr92.53 Million | Nkr-19.05 Million | -0.206x | -104.92% |
| 2010-12-31 | Nkr105.42 Million | Nkr-10.59 Million | -0.100x | +79.07% |
| 2009-12-31 | Nkr35.08 Million | Nkr-16.84 Million | -0.480x | -151.50% |
| 2008-12-31 | Nkr49.30 Million | Nkr-9.41 Million | -0.191x | -- |